語系:
繁體中文
English
說明(常見問題)
登入
回首頁
切換:
標籤
|
MARC模式
|
ISBD
Asthma = targeted biological therapies /
~
Vatrella, Alessandro.
Asthma = targeted biological therapies /
紀錄類型:
書目-語言資料,印刷品 : Monograph/item
正題名/作者:
Asthma/ by Girolamo Pelaia, Alessandro Vatrella, Rosario Maselli.
其他題名:
targeted biological therapies /
作者:
Pelaia, Girolamo.
其他作者:
Vatrella, Alessandro.
出版者:
Cham :Springer International Publishing : : 2017.,
面頁冊數:
vi, 99 p. :ill., digital ; : 24 cm.;
Contained By:
Springer eBooks
標題:
Asthma - Treatment. -
電子資源:
http://dx.doi.org/10.1007/978-3-319-46007-9
ISBN:
9783319460079
Asthma = targeted biological therapies /
Pelaia, Girolamo.
Asthma
targeted biological therapies /[electronic resource] :by Girolamo Pelaia, Alessandro Vatrella, Rosario Maselli. - Cham :Springer International Publishing :2017. - vi, 99 p. :ill., digital ;24 cm.
Introduction -- Inflammatory cellular patterns in asthma -- Airway remodelling in asthma -- Anti-IgE antibodies -- IL-5-targeted antibodies -- IL-4-specific biologics -- Anti-IL-13 therapies -- Anti-TNFalpha-antibodies -- Biologic treatments targeted to innate cytokines -- Other biologic drugs -- Conclusions and future perspectives.
This book focuses on the fundamentals of the use of biologics in asthma, describing the rationale, principles, mechanisms of action, and indications. It offers an excellent balance between basic science and the analysis of clinical trials, updating readers with new developments that are changing the global scenario for targeted biological anti-asthma therapies, especially with regard to more severe disease. A range of therapies are considered, from the humanized monoclonal anti-IgE antibody omalizumab, widely approved as add-on treatment for inadequately controlled disease, through to emerging biologics for which evidence supportive of efficacy is accumulating, including anti-IL-5, anti-IL-4, and anti-IL-13 therapies. One aspect to emerge is the variability in individual response, which suggests a need for characterization of different asthma subtypes to permit the effective implementation of phenotype-targeted treatments. This book will be of interest for pulmonologists, clinical immunologists, and physicians seeking sound information on these therapies, but also for scientists and pharmacologists wishing to enhance their knowledge of the therapeutic implications of the cellular and molecular mechanisms that underlie severe, uncontrolled asthma.
ISBN: 9783319460079
Standard No.: 10.1007/978-3-319-46007-9doiSubjects--Topical Terms:
790117
Asthma
--Treatment.
LC Class. No.: RC591
Dewey Class. No.: 616.23806
Asthma = targeted biological therapies /
LDR
:02538nam a2200313 a 4500
001
957424
003
DE-He213
005
20161112033317.0
006
m d
007
cr nn 008maaau
008
201118s2017 gw s 0 eng d
020
$a
9783319460079
$q
(electronic bk.)
020
$a
9783319460055
$q
(paper)
024
7
$a
10.1007/978-3-319-46007-9
$2
doi
035
$a
978-3-319-46007-9
040
$a
GP
$c
GP
041
0
$a
eng
050
4
$a
RC591
072
7
$a
MJL
$2
bicssc
072
7
$a
MED079000
$2
bisacsh
082
0 4
$a
616.23806
$2
23
090
$a
RC591
$b
.P381 2017
100
1
$a
Pelaia, Girolamo.
$3
1249001
245
1 0
$a
Asthma
$h
[electronic resource] :
$b
targeted biological therapies /
$c
by Girolamo Pelaia, Alessandro Vatrella, Rosario Maselli.
260
$a
Cham :
$c
2017.
$b
Springer International Publishing :
$b
Imprint: Springer,
300
$a
vi, 99 p. :
$b
ill., digital ;
$c
24 cm.
505
0
$a
Introduction -- Inflammatory cellular patterns in asthma -- Airway remodelling in asthma -- Anti-IgE antibodies -- IL-5-targeted antibodies -- IL-4-specific biologics -- Anti-IL-13 therapies -- Anti-TNFalpha-antibodies -- Biologic treatments targeted to innate cytokines -- Other biologic drugs -- Conclusions and future perspectives.
520
$a
This book focuses on the fundamentals of the use of biologics in asthma, describing the rationale, principles, mechanisms of action, and indications. It offers an excellent balance between basic science and the analysis of clinical trials, updating readers with new developments that are changing the global scenario for targeted biological anti-asthma therapies, especially with regard to more severe disease. A range of therapies are considered, from the humanized monoclonal anti-IgE antibody omalizumab, widely approved as add-on treatment for inadequately controlled disease, through to emerging biologics for which evidence supportive of efficacy is accumulating, including anti-IL-5, anti-IL-4, and anti-IL-13 therapies. One aspect to emerge is the variability in individual response, which suggests a need for characterization of different asthma subtypes to permit the effective implementation of phenotype-targeted treatments. This book will be of interest for pulmonologists, clinical immunologists, and physicians seeking sound information on these therapies, but also for scientists and pharmacologists wishing to enhance their knowledge of the therapeutic implications of the cellular and molecular mechanisms that underlie severe, uncontrolled asthma.
650
0
$a
Asthma
$x
Treatment.
$3
790117
650
1 4
$a
Medicine & Public Health.
$3
593949
650
2 4
$a
Pneumology/Respiratory System.
$3
668561
650
2 4
$a
Allergology.
$3
673940
650
2 4
$a
Pharmacology/Toxicology.
$3
593882
650
2 4
$a
General Practice / Family Medicine.
$3
593966
650
2 4
$a
Pediatrics.
$3
644839
700
1
$a
Vatrella, Alessandro.
$3
1249002
700
1
$a
Maselli, Rosario.
$3
1249003
710
2
$a
SpringerLink (Online service)
$3
593884
773
0
$t
Springer eBooks
856
4 0
$u
http://dx.doi.org/10.1007/978-3-319-46007-9
950
$a
Medicine (Springer-11650)
筆 0 讀者評論
多媒體
評論
新增評論
分享你的心得
Export
取書館別
處理中
...
變更密碼[密碼必須為2種組合(英文和數字)及長度為10碼以上]
登入